Cohort Profile Update: The Bissau HIV Cohort—a cohort of HIV-1, HIV-2 and co-infected patients.

Of all HIV patients, 10.3% are HIV-2 infected (18% in the original cohort), 7.3% are HIV 1/2 dually infected (11% in the original cohort) and 74.2% are HIV-1 infected (69% in the original cohort). Performance of Bio-Rad HIV-1/2 Confirmatory Assay in HIV-1, HIV-2 and HIV-1/2 dually reactive patients: comparison with INNO-LIA and immunocomb discriminatory assays. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. Key Features The Bissau HIV Cohort was established in 2007 as a single-centre cohort in the capital city Bissau in Guinea-Bissau, to gain insight into the effect of introducing antiretroviral treatment in a treatment-naïve population concomitantly infected with retroviruses [human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2) and human t-lympotropic virus 1 (HTLV-1)] and tuberculosis. [Extracted from the article]